SUMMARY Endotoxin-stimulated nitroblue tetrazolium (NBT) reduction was evaluated in 853 individuals: 270 healthy controls, 334 with various non-neoplastic conditions, 220 with solid non-lymphomatous tumours, and 29 with lymphoma. Each of the above groups was divided into three age subgroups: < 60, 60-69, and > 70 years.
According to recent observations made in our laboratory, peripheral polymorphonuclear leucocytes (PMNs) from patients with solid cancer have a diminished capacity to reduce nitroblue tetrazolium (NBT) dye to formazan when maximally stimulated with endotoxin (Haim et al., 1977a (Haim et al., , 1977b . This impaired leucocytic reactivity was found in both treated and untreated patients, in patients with active malignancy, as well as in cured cancer patients.
The above findings prompted us to conduct a comparative study of endotoxin-stimulated NBT reduction values in relatively large groups of patients with cancer, in patients with a variety of non-malignant conditions, and in healthy subjects. Special emphasis was given to (Baehner and Nathan, 1968) , malignant processes (Humbert et al., 1976; Haim et al., 1977a Haim et al., , 1977b , and others (Shousha and Kamel, 1972; Curreri et al., 1973; Gray et al., 1973; Tan et al., 1973) . Our study, however, reveals that the validity of this test in studying leucocyte abnormalities in advanced age is questionable since the difference in the reduction capacity between disease and health becomes blurred in old subjects.
The effect of age on PMNs' function is as yet inconclusive. Kauffman et al. (1977) reported a decreased bactericidal capacity of leucocytes in elderly subjects. Eschenbach et al. (1975) , on the other hand, found that the capacity of NBT reduction of neutrophils is independent of age. An analysis of the values of endotoxin-stimulated NBT reduction in the present group of healthy control subjects clearly demonstrated that stimulated NBT reduction capacity declines with advancing age, especially over 70 years. It is noteworthy that various parameters of cell-mediated immunity are also known to be depressed in old subjects (Roberts-Thomson et al., 1974) .
A similar age-related reduction capacity, though less pronounced, was also noted in the group of patients with non-malignant diseases. On the other hand, no such relationship was evident in cancer patients. Perhaps in these patients the ability of leucocytes to reduce NBT is already depressed by the underlying disease, and no further agerelated depression could be expected.
NBT reduction in cancer patients was obviously lower than in the group of patients with nonmalignant diseases. In accordance with our previous studies (Haim et al., 1977a (Haim et al., , 1977b , the present study also showed a diminished reduction capacity in cancer patients, who were clinically free of tumour at the time of testing. It is worth noting that leucocyte alkaline phosphatase (LAP) activity was also found to be decreased in patients with solid tumours who had no evidence of disease when studied (Lokich, 1977 ). An enhanced spontaneous NBT reduction and phagocyte killing capacity has been frequently reported in patients with lymphoma (Silverman and Reed, 1973; Chang et al., 1974; Hancock et al., 1976; Steigbigel et al., 1976) . In our study, the capacity of reduction in these cases was comparable to that in healthy controls and markedly higher than in patients with other solid tumours. It seems, therefore, that malignant lymphoma differs from non-lymphomatous malignancy with regard to stimulated NBT reduction.
The individual variation in healthy controls was great (range 11-68% in subjects under 60). Hence, the lower limit below which the stimulated NBT score should be considered pathological is as yet undetermined, and the test cannot serve as a quantitative indicator of PMNs' function in individual patients. 
